UroGen Pharma Ltd. has increased the size of its board of directors from eight to nine and appointed James A. Robinson Jr. as a director until the 2023 Annual Meeting of Shareholders. Robinson has also been assigned to the Compliance Committee of the Board. He received an initial option grant to purchase 20,000 ordinary shares, which will vest in equal quarterly installments for the next three years. Moreover, he will receive an annual retainer of $45,000 for his services to the Board and Compliance Committee and an option grant to purchase 10,000 Ordinary Shares annually.